{"success":true,"data":{"pressRelease":{"id":"140592","rtpr_id":"nGNEkHpzz-20260910","ticker":"TECN","exchange":"","all_tickers":["TECN"],"title":"Tecan to participate in upcoming Investor Conference","author":"Globe Newswire","published_at":"2026-09-10T13:45:00.058Z","article_body":"Männedorf, Switzerland, September 10, 2026 – The Tecan Group (SIX Swiss\nExchange: TECN) today announced that it will participate in the following\ninvestor conference next week:\n\n24(th) Annual Morgan Stanley Healthcare Conference, New York, USA\nDate: September 14, 2026\nTime: 2:35pm EDT (8:35pm CEST)\nFormat: Fireside chat with Monica Manotas, CEO, and the Morgan Stanley analyst\nAdditional participants: Camila Japur, CFO & Martin Braendle, SVP, Corp. Comm.\n& Investor Relations\nWebcast live under the \"Investor Relations\" tab of Tecan's website\nwww.tecan.com. \nA replay of the webcast will be available after the presentation and will\nremain available for 120 days.\n\nAbout Tecan\n\nTecan (www.tecan.com) improves people’s lives and health by empowering\ncustomers to scale healthcare innovation globally from life science to the\nclinic. Tecan is a pioneer and global leader in laboratory automation. As an\noriginal equipment manufacturer (OEM), Tecan is also a leader in developing\nand manufacturing OEM instruments, components and medical devices that are\nthen distributed by partner companies. Founded in Switzerland in 1980, the\ncompany has more than 3,000 employees, with manufacturing, research and\ndevelopment sites in Europe, North America and Asia, and maintains a sales and\nservice network in over 70 countries. In 2025, Tecan generated sales of CHF\n883 million (USD 1,063 million; EUR 939 million). Registered shares of Tecan\nGroup are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).\n        \n        \nFor further information:\n\nTecan Group\nMartin Brändle\nSenior Vice President, Corporate Communications & IR\nTel. +41 (0) 44 922 84 30\nFax +41 (0) 44 922 88 89\ninvestor@tecan.com\nwww.tecan.com\n\nAttachment\n*     Press Release\n(https://ml-eu.globenewswire.com/Resource/Download/6f022722-cd1d-4406-a523-4ca599a52acb)","article_body_html":"","raw_payload":{"data":{"id":"nGNEkHpzz-20260910","title":"Tecan to participate in upcoming Investor Conference","author":"Globe Newswire","ticker":"TECN","created":"2026-09-10T13:45:00.058Z","tickers":["TECN"],"exchange":"","article_body":"Männedorf, Switzerland, September 10, 2026 – The Tecan Group (SIX Swiss\nExchange: TECN) today announced that it will participate in the following\ninvestor conference next week:\n\n24(th) Annual Morgan Stanley Healthcare Conference, New York, USA\nDate: September 14, 2026\nTime: 2:35pm EDT (8:35pm CEST)\nFormat: Fireside chat with Monica Manotas, CEO, and the Morgan Stanley analyst\nAdditional participants: Camila Japur, CFO & Martin Braendle, SVP, Corp. Comm.\n& Investor Relations\nWebcast live under the \"Investor Relations\" tab of Tecan's website\nwww.tecan.com. \nA replay of the webcast will be available after the presentation and will\nremain available for 120 days.\n\nAbout Tecan\n\nTecan (www.tecan.com) improves people’s lives and health by empowering\ncustomers to scale healthcare innovation globally from life science to the\nclinic. Tecan is a pioneer and global leader in laboratory automation. As an\noriginal equipment manufacturer (OEM), Tecan is also a leader in developing\nand manufacturing OEM instruments, components and medical devices that are\nthen distributed by partner companies. Founded in Switzerland in 1980, the\ncompany has more than 3,000 employees, with manufacturing, research and\ndevelopment sites in Europe, North America and Asia, and maintains a sales and\nservice network in over 70 countries. In 2025, Tecan generated sales of CHF\n883 million (USD 1,063 million; EUR 939 million). Registered shares of Tecan\nGroup are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).\n        \n        \nFor further information:\n\nTecan Group\nMartin Brändle\nSenior Vice President, Corporate Communications & IR\nTel. +41 (0) 44 922 84 30\nFax +41 (0) 44 922 88 89\ninvestor@tecan.com\nwww.tecan.com\n\nAttachment\n*     Press Release\n(https://ml-eu.globenewswire.com/Resource/Download/6f022722-cd1d-4406-a523-4ca599a52acb)"},"type":"article","timestamp":"2026-09-10T13:45:00.150096205Z","server_sent_at_ms":1789047900150},"received_at":"2026-09-10T13:45:00.205Z","source_url":null},"analysis":{"id":"129428","press_release_id":"140592","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Tecan Group will present at the 24th Annual Morgan Stanley Healthcare Conference in New York on September 14, 2026, with a 2:35pm EDT fireside chat featuring CEO Monica Manotas.\n\nCFO Camila Japur and SVP of Corporate Communications & IR Martin Braendle will also attend; the session will be webcast live via Tecan's investor relations site, with a replay available for 120 days.\n\nThe release contains no new financial disclosures — Tecan, a laboratory automation leader, generated CHF 883 million (USD 1,063 million) in 2025 sales per the boilerplate section.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference-participation notice with no incremental information — monitor the fireside chat webcast only for unexpected guidance color."},"keyFigures":{"customDimensions":{"employees":"more than 3,000","fy2025_sales":"CHF 883 million (USD 1,063 million; EUR 939 million)","countries_served":"over 70","webcast_replay_availability_days":120}},"namedEntities":{"people":[{"name":"Monica Manotas","role":"CEO"},{"name":"Camila Japur","role":"CFO"},{"name":"Martin Braendle","role":"SVP, Corporate Communications & Investor Relations"}],"products":[],"companies":[{"name":"Tecan Group","ticker":"TECN","relationship":"filer"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[{"amount":"CHF 883 million","context":"Tecan 2025 sales"},{"amount":"USD 1,063 million","context":"Tecan 2025 sales in USD equivalent"},{"amount":"EUR 939 million","context":"Tecan 2025 sales in EUR equivalent"}]},"materialImpact":{"score":1,"reasoning":"Routine scheduling announcement for investor-conference participation with a webcast. Contains no new financial results, guidance, or strategic developments beyond boilerplate company facts."},"tickerRelevance":{"others":[],"primary":"TECN"},"globalImportance":12,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"foreign mid-cap (SIX Swiss Exchange listed)","eventGravity":"routine conference participation notice","issuerAuthored":true,"foreignIssuerDiscount":true,"newInformationContent":"none — scheduling and boilerplate only"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Tecan Group will present at the 24th Annual Morgan Stanley Healthcare Conference in New York on September 14, 2026, with a 2:35pm EDT fireside chat featuring CEO Monica Manotas.\n\nCFO Camila Japur and SVP of Corporate Communications & IR Martin Braendle will also attend; the session will be webcast live via Tecan's investor relations site, with a replay available for 120 days.\n\nThe release contains no new financial disclosures — Tecan, a laboratory automation leader, generated CHF 883 million (USD 1,063 million) in 2025 sales per the boilerplate section.","key_figures":{"customDimensions":{"employees":"more than 3,000","fy2025_sales":"CHF 883 million (USD 1,063 million; EUR 939 million)","countries_served":"over 70","webcast_replay_availability_days":120}},"named_entities":{"people":[{"name":"Monica Manotas","role":"CEO"},{"name":"Camila Japur","role":"CFO"},{"name":"Martin Braendle","role":"SVP, Corporate Communications & Investor Relations"}],"products":[],"companies":[{"name":"Tecan Group","ticker":"TECN","relationship":"filer"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[{"amount":"CHF 883 million","context":"Tecan 2025 sales"},{"amount":"USD 1,063 million","context":"Tecan 2025 sales in USD equivalent"},{"amount":"EUR 939 million","context":"Tecan 2025 sales in EUR equivalent"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-10T13:45:25.964Z","global_importance":12,"audience_relevance":12,"importance_components":{"tickerTier":"foreign mid-cap (SIX Swiss Exchange listed)","eventGravity":"routine conference participation notice","issuerAuthored":true,"foreignIssuerDiscount":true,"newInformationContent":"none — scheduling and boilerplate only"}},"durationMs":25757,"modelName":"glm-5.3-flash"}}